Form 53-901F (British Columbia)
Form 27 (Alberta, Ontario and Nova Scotia)

MATERIAL CHANGE REPORT PURSUANT TO

Subsection 85(1) of the *Securities Act*, R.S.B.C. 1996, c. 418
Subsection 146(1) of the *Securities Act*, R.S.A. 1981, c. S-6.1
Subsection 75(2) of the *Securities Act*, R.S.O. 1990, c. S.5
Subsection 81(2) of the *Securities Act*, R.S. N.S. 1989, c. 418

Item 1. Reporting Issuer

1091089 Alberta Ltd. (wholly-owned subsidiary of MedMira Inc.)
c/o MedMira Inc. (the "Corporation")
155 Chain Lake Drive
Suite 1
Halifax, Nova Scotia
B3S 1B3

Item 2. Date of Material Changes

February 12, 2004

Item 3. Press Release

The attached form of press release was issued in Halifax, Nova Scotia on February 12, 2004.

Item 4. Summary of Material Changes

The Corporation announced the completion of the acquisition of 100% of the outstanding common shares of Seneca Equities Corporation ("Seneca") of Calgary, Alberta, completing a qualifying transaction for Seneca. The combined companies will continue to operate under the MedMira name. While the transaction has received conditional approval, the acquisition is subject to the final approval of the TSX Venture Exchange and compliance with the requirements of applicable securities laws.

Item 5. Full Description of Material Changes

The acquisition, valued at $314,179, represents the net cash position of Seneca. MedMira will issue 293,626 common shares and common share rights, at a price of $1.07, in exchange for 100% of the outstanding common shares of Seneca. This price represents a 26% premium, based on the February 11, 2004 closing price of MedMira shares.

The common share rights, which must be exercised within 30 days, entitle the holder to purchase one common share of MedMira at an exercise price of $0.96, and to receive one common share warrant. The warrants have a 1-year term and entitle the holder to purchase one common share at a price on $1.07.

Item 6. Reliance on subsection 75(3) of the *Securities Act* (Ontario)

N/A

Item 7. Omitted Information

N/A

Item 8. Senior Officer / Director

Mr. William Gullage
902-450-1588

Item 9. Statement of Senior Officer / Director

The foregoing accurately discloses the material changes referred to herein.

Dated at Toronto, Ontario this 23rd day of February, 2004.

[*signed*] William Gullage
William Gullage
Director

News release via Canada NewsWire, Halifax 902-422-1411

Attention Business Editors:
MedMira To Acquire The Assets Of Seneca Equities Of Calgary, Alberta

HALIFAX, Feb. 12 /CNW/ - MedMira Inc. ("MedMira") (TSX Venture: MIR) today announced completion of the acquisition of 100% of the outstanding common shares of Seneca Equities Corp. ("Seneca") of Calgary, Alberta, completing a qualifying transaction for Seneca. The combined companies will continue to operate under the MedMira name. While the transaction has received conditional approval, the acquisition is subject to the final approval of the TSX Venture Exchange and compliance with the requirements of applicable securities laws.

The transaction, valued at $314,179 represents the net cash position of Seneca. MedMira will issue 293,626 common shares and common share rights, at a price of $1.07 in exchange for 100% of the outstanding common shares of Seneca. This price represents a 26% premium, based on the February 11, 2004 closing price of MedMira shares.

The common share rights, which must be exercised within 30 days, entitle the holder to purchase one common share of MedMira at an exercise price of $0.96 and to receive one common share warrant. The warrants have a 1-year term and entitle the holder to purchase one common share at price on $1.07.

"We're very pleased to have the opportunity to invest directly in MedMira," said Joe Giuffre, President of Seneca, "as we believe the company has a bright future, with a versatile health technology that is beginning to have success in major markets throughout the world."

"We see this as a great opportunity to further expand our considerable shareholder base in western Canada," said Stephen Sham, Chairman and CEO of MedMira, "and we take this to be a strong vote of confidence by sophisticated investors in the company and in the potential of our expanding product line."

MedMira (www.medmira.com) is a commercial biotechnology company that develops, manufactures and markets qualitative, in vitro diagnostic tests for the detection of antibodies to certain diseases, such as HIV, in human serum, plasma or whole blood. The United States FDA and the SFDA in the People's Republic of China have approved MedMira's Reveal(TM) and MiraWell(TM) Rapid HIV Tests, respectively.

All of MedMira's diagnostic tests are based on the same flow-through technology platform, thus facilitating the development of future products. MedMira's technology provides a quick (under 3 minutes), accurate, portable, safe and cost-effective alternative to conventional laboratory testing.

This news release contains forward-looking statements, which involve risk and uncertainties and reflect the company's current expectation regarding future events. Actual events could materially differ from those projected herein and depend on a number of factors including, but not limited to, changing market conditions, successful and timely completion of clinical studies, uncertainties related to the regulatory approval process, establishment of corporate alliances and other risks detailed from time to time in the company quarterly filings.

The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of this statement.

%SEDAR: 00013053E

/For further information: MedMira: Dr. James Smith: (902) 450-1588 or e-mail: ir(at)medmira.com; Seneca Equities: Mr. Joe Giuffre, President and Director, (403) 279-0099, e-mail: sameva7(at)aol.com/

(MIR. SEN)

CO: MedMira Inc.; Seneca Equities Corp.

CNW 16:56e 12-FEB-04